Table 4.

Multivariate analysis of EFS and OS in chemotherapy-only group and allo-HSCT group.

Variables	EFS			OS
	HR(95%CI)	P-value		HR(95%CI)	P-value
Chemotherapy-only group
SPNS2	3.072 (1.378-6.851)	0.006		1.884 (1.006-3.526)	0.048
SPNS3	1.525 (0.737-3.156)	0.225		1.287 (0.728-2.276)	0.386
PB (≥20 vs. <20 × 10%)	0.680 (0.341-1.359)	0.275		0.653 (0.374-1.140)	0.134
FLT3-ITD (positive vs. negative)	0.889 (0.398-1.988)	0.775		0.863 (0.443-1.681)	0.666
NPM1 (mutated vs. wild)	0.870 (0.398-1.948)	0.736		0.875 (0.473-1.617)	0.670
DNMT3A (mutated vs. wild)	1.265 (0.595-2.687)	0.541		1.626 (0.920-2.871)	0.094
TET2 (mutated vs. wild)	0.476 (0.161-1.410)	0.180		0.619 (0.296-1.294)	0.202
Allo-HSCT
SPNS3	1.092 (0.289-4.126)	0.897		2.789 (1.257-5.339)	0.002
Age (≥60 vs. <60 years)	0.740 (0.235-2.331)	0.607		1.061 (0.560-2.010)	0.856
PB (≥20 vs. <20 × 10%)	0.428 (0.149-1.227)	0.114		0.774 (0.404-1.481)	0.439
FLT3-ITD (positive vs. negative)	2.068 (0.450-9.508)	0.351		2.359 (1.062-5.240)	0.035
NPM1 (mutated vs. wild)	0.597 (0.132-2.697)	0.502		0.502 (0.214-1.174)	0.112
IDH1/IDH2 (mutated vs. wild)	1.456 (0.407-5.204)	0.563		0.789 (0.364-1.707)	0.547
RUNX1(mutated vs. wild)	2.275 (0.415-12.468)	0.344		1.529 (0.614-3.807)	0.361

EFS event-free survival, OS overall survival, HR hazard ratio, CI confidential interval, PB peripheral blood